The principles of psoriatic arthritis (PsA) treatment include reducing pain, improving quality of life, preventing structural damage and complications, engaging patients in shared decision-making, and identifying comorbidities that may impact treatment decisions. This requires management by a multidisciplinary team. Novel agents and treatment targets have demonstrated efficacy in PsA. Education is needed to ensure that the most up-to-date evidence informs treatment decision-making to optimize patient outcomes.
In this CMEOCast podcast, expert faculty will present key clinical efficacy and safety data for novel and emerging agents and discuss how best to apply this data to treatment decisions in patients with PsA.
At the end of this CME/CE activity, participants should be able to apply key clinical efficacy and safety data for novel and emerging agents to treatment decisions in patients with PsA.
The following learning objectives pertain only to those requesting CNE or CPE credit: Summarize the key clinical efficacy and safety data for novel and emerging agents for PsA.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Rheumatologists, dermatologists, PAs, nurse practitioners, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Dr. Armstrong reports that she receives grants or research support from AbbVie Inc.; Boehringer Ingelheim/Parexel; Bristol-Myers Squibb Company; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; Galderma; Janssen-Ortho, Inc.; Janssen Pharmaceuticals, Inc.; Kyowa Hakko Kirin; Leo Pharma Inc.; Modernizing Medicine; Novartis; Ortho Dermatologics; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharma, and UCB Pharma. She is on the speakers bureau for AbbVie Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.